logo
Prediction: Palantir Stock Will Plunge to $55 by 2027

Prediction: Palantir Stock Will Plunge to $55 by 2027

Yahoo5 hours ago

Productivity improvements and consumption-side effects from the rise of artificial intelligence (AI) can add $15.7 trillion to the global economy come 2030, according to one estimate.
Investors have flocked to Palantir Technologies stock due to its sustained moat, cash-rich balance sheet, and ideal positioning with Donald Trump as president..
However, two historically insurmountable catalysts are expected to weigh heavily on Palantir stock in the coming years.
10 stocks we like better than Palantir Technologies ›
For more than two years, no trend has captivated the attention and pocketbooks of investors quite like the rise of artificial intelligence (AI). The ability for AI-empowered software and systems to make split-second decisions without the oversight of humans is a technology with broad-reaching potential in most industries around the globe.
In Sizing the Prize, the analysts at PwC estimate a combination of productivity improvements and consumption-side effects from AI will boost worldwide gross domestic product by 26%, or $15.7 trillion, come 2030. If this figure is even remotely accurate, it means a long list of companies will benefit from this game-changing technology.
Although graphics processing unit (GPU) kingpin Nvidia is often viewed as the face of the AI revolution, a strong argument can be made that it's been surpassed by AI- and machine learning-driven data-mining specialist Palantir Technologies (NASDAQ: PLTR). When 2023 began, Palantir was a company of fringe importance in the tech sector. But following a greater than 2,000% gain in two and a half years, it's become the eighth-largest publicly traded U.S. tech stock.
But in spite of everything seemingly going its way, it's my expectation that Palantir stock will plunge to $55 (representing a decline of 60%), at minimum, by 2027.
However, before making predictions about the future, it's imperative to understand how Palantir's $330 billion market cap foundation was built.
The primary reason Wall Street and investors love Palantir so much is simple: it offers a sustainable moat. The company's two core operating segments -- Gotham and Foundry -- lack large-scale competition. When public companies have no clear one-for-one replacement and don't have to look over their proverbial shoulder, they tend to be rewarded with a hefty premium by the investing community.
Something else Palantir brings to the table that investors seem to appreciate is its operating cash flow predictability. Gotham, which services federal governments by aiding with mission planning and execution, as well as data collection/analysis, typically lands multiyear contracts. Meanwhile, the enterprise-focused Foundry platform, which helps businesses better understand their data, is a subscription-based model. Wall Street loves predictability, and a lot of Palantir's sales can be forecast multiple years in advance.
Speaking of forecasting, Palantir shifted to recurring profits well ahead of the consensus from Wall Street analysts. The company has demonstrated that its operating model is viable and time-tested.
Another reason investors have piled in is the company's pristine balance sheet. Palantir Technologies closed out the March-ended quarter with $5.43 billion in cash, cash equivalents, and marketable securities, with no debt. This mammoth cash pile allows CEO Alex Karp to aggressively invest in platform innovation(s), as well as reward shareholders with occasional stock buybacks.
The icing on the cake for Wall Street and investors -- aside from Palantir's sustained annual sales growth of between 25% and 35% -- is Donald Trump's November victory. Historically, Republican-led governments have favored strong defense spending. Further, Trump is a big proponent of national security and making America an AI leader. It's the ideal situation for Gotham (Palantir's leading platform) to thrive.
When viewed with a wide lens, Palantir is a fantastic business with a sustainable moat that's utilizing AI and machine learning to sustain a double-digit sales growth rate. But even fantastic businesses can run into historical headwinds.
While I don't deny that Palantir is cash-rich, profitable, and capable of sustaining its competitive moat, its premium valuation will almost certainly come under pressure over the next two years due to two factors.
To begin with, there hasn't been a game-changing technological innovation or hyped trend for more than three decades that's managed to avoid an early stage bubble-bursting event. In other words, every major technological advancement since (and including) the advent of the internet in the mid-1990s has seen investors overestimate early innings adoption and/or utility.
There's no question America's most-influential businesses have an appetite for AI hardware and applications at the moment. Nvidia's skyrocketing sales are evidence of businesses wanting to be on the leading edge of the AI revolution within their respective industries. But what we're not seeing is evidence of businesses optimizing their AI solutions or consistently generating a positive return on their AI investments. Without exception, every next-big-thing technology has needed time to mature, and AI simply isn't there yet.
The good news for Palantir is its multiyear contracts via Gotham and subscriptions from Foundry would help insulate its top-line results from an immediate drop-off if the AI bubble bursts. Unfortunately, investor sentiment would still be expected to weigh heavily on Palantir stock, if history were to repeat.
The second significant downside catalyst for Palantir stock, based on what history has to say, is its valuation. Although a premium valuation multiple is warranted for companies that boast a sustainable moat, Palantir stock has pushed this premium into the stratosphere.
Prior to the bursting of the dot-com bubble a quarter of a century ago, prominent internet-driven businesses like Microsoft, Cisco Systems, and Amazon saw their respective price-to-sales (P/S) ratios catapult higher. Something similar occurred with AI-GPU giant Nvidia last summer. Though their trailing-12-month (TTM) P/S ratio peaks all occurred at different times, these four companies topped out at TTM P/S ratios ranging from about 30 to 43.
As of the closing bell on June 20, Palantir's TTM P/S ratio was tipping the scales at (drum roll) 110! No megacap company on the leading edge of a next-big-thing trend has been able to maintain a TTM P/S ratio of 30 to 40 for a considerable length of time, let alone a triple-digit figure.
Even if Palantir were to meet Wall Street's consensus forecast, which calls for cumulative sales growth of 132% from 2024 ($2.87 billion, actual) to 2027 ($6.65 billion, estimated), it would still be valued at a well-above-average multiple of 20 times sales in 2027 at $55 per share.
Though it's impossible to pinpoint when the music will slow or stop for Palantir, history couldn't be clearer that a big-time decline is in order.
Before you buy stock in Palantir Technologies, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!*
Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of June 23, 2025
John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Sean Williams has positions in Amazon. The Motley Fool has positions in and recommends Amazon, Microsoft, Nvidia, and Palantir Technologies. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Prediction: Palantir Stock Will Plunge to $55 by 2027 was originally published by The Motley Fool

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Udemy Expands Leadership Team With Three Key Appointments to Accelerate AI-Powered Transformation
Udemy Expands Leadership Team With Three Key Appointments to Accelerate AI-Powered Transformation

Yahoo

time4 minutes ago

  • Yahoo

Udemy Expands Leadership Team With Three Key Appointments to Accelerate AI-Powered Transformation

Former Airbnb, YouTube, and Google Executive, Sonya Saunder, Brings Strategic Growth and Operational Excellence to Accelerate Udemy's Focus on Subscription and AI as Chief of Staff and VP of Strategy & Operations Industry Veteran Ann-Marie Darrough brings Deep Experience Executing and Scaling International Partnership Programs from IBM and Coveo to Udemy as VP of Global Partnerships Enterprise Partnership Veteran and Former Leader at SAP, Blaine Trainor, to Build Udemy's Technology Integration Ecosystem and Focus on Driving Enterprise Platform Growth as VP of Partner Ecosystems SAN FRANCISCO, June 24, 2025--(BUSINESS WIRE)--Udemy (Nasdaq: UDMY), a leading AI-powered skills development platform, announced the appointment of Sonya Saunder as Chief of Staff and Vice President of Strategy & Operations, Ann-Marie Darrough as Vice President of Global Partnerships and Blaine Trainor as Vice President of Partner Ecosystems. These strategic hires further strengthen Udemy's leadership team as the company accelerates its transformation into a world-class, AI-powered platform to reskill and upskill the future workforce. "As we continue to evolve our platform and extend our global reach, we are expanding our team with experienced leaders who can drive strategic initiatives and forge valuable partnerships," said Hugo Sarrazin, President and CEO of Udemy. "Sonya, Ann-Marie and Blaine bring a wealth of experience from some of the world's most innovative companies. We look forward to their valuable contributions as we work towards scaling our AI-powered learning ecosystem and creating more value for customers worldwide." Sonya Saunder - Chief of Staff and VP of Strategy & Operations As Chief of Staff and VP of Strategy & Operations, Sonya Saunder will be responsible for developing and refining Udemy's corporate strategy in partnership with the executive team to drive long-term growth and profitability at scale. She will also be responsible for driving the execution of key growth initiatives while putting in place operating systems to support them. Saunder joins Udemy from Airbnb, where she served as Director of Business Operations and Programs, directing growth strategies for high-quality supply and establishing scalable operating systems. Prior to Airbnb, Saunder held leadership positions at YouTube as Head of Strategy, Operations & Chief of Staff, where she managed strategy and operations for a 1,000+ member product organization and led annual strategy planning for major cross-team initiatives. Her extensive experience also includes various leadership roles at Google, including Head of Search International Growth, where she built and scaled the strategy function for growth initiatives in markets like Japan and India, and Chief of Staff for Search. Ann-Marie Darrough - VP of Global Partnerships As VP of Global Partnerships, Ann-Marie Darrough will be responsible for leading Udemy's global partner strategy and execution, with a focus on scaling revenue through both content sales and platform fees. She will design and implement global partner strategies that align with Udemy's strategy. Darrough will lead efforts to expand Udemy's footprint in key markets across the globe and work closely with Sales, Product, Marketing, Revenue Operations, and Customer Success teams to align on go-to-market initiatives. Darrough joins Udemy from Coveo, a cloud-based AI platform that enhances digital experiences by providing intelligent search, recommendations, and personalized content delivery, where she served as VP of Alliances & Partnerships. Darraugh was responsible for establishing partnerships with a focus on growing strategic Independent Software Vendors (ISV) and Global Systems Integrator (GSI) partnerships, technology partners and hyperscalers, while establishing partnerships with large enterprises and Fortune 500 companies. She successfully designed and executed a global partner program to scale strategic alliances, significantly increasing partner-sourced revenue growth as a percent of bookings. Previously, Darrough was Global GTM VP, Solution Consulting, Strategy and Enablement at Bloomreach, where she scaled revenue by expanding alliances and refining go-to-market efforts. Her extensive experience also includes over 15 years at IBM, where she held various leadership positions, including Director of Offering Management, spearheading product and GTM strategies for IBM Collaboration and Commerce Solutions and developing key partnerships. Blaine Trainor - VP of Partner Ecosystems Blaine Trainor brings deep experience in e-commerce and enterprise technology to Udemy. In this role, Trainor will be responsible for leading Udemy's technology partnership strategy and execution. He will focus on building and scaling a robust ecosystem of technology integrations that drive platform adoption and revenue growth. Before joining Udemy, Trainor served as VP of Partnerships at Zowie, which provides customer service solutions, primarily through its AI-powered platform for enterprises, that aims to automate complex support tasks across various channels, where he developed strategic alliance programs and drove partnership-led revenue growth. Prior to Zowie, Trainor was Global Vice President of Partnerships and Alliances at commercetools, where he successfully led a global team covering GSI, ISV and Cloud & Infrastructure partners, which transformed the team into a leading source of quality pipeline. Trainor previously served in various senior roles at SAP, where he evolved the partnership function by closely aligning with sales teams, which ultimately led to significant partner-generated revenue growth. His extensive career also includes leadership positions at IBM, where he developed deep expertise in complex enterprise deals and sales cycles. About Udemy Udemy (Nasdaq: UDMY) is an AI-driven skills development platform transforming how companies and individuals across the world build the capabilities needed to thrive in a rapidly evolving workplace. By combining on-demand, multi-language content with real-time innovation, Udemy delivers personalized experiences that empower organizations to scale workforce development and help individuals build the technical, business, and soft skills most relevant to their careers. Today, thousands of companies, including Ericsson, Glassdoor, On24, The World Bank, and Volkswagen, rely on Udemy Business for its enterprise solutions to build agile, future-ready teams. Udemy is headquartered in San Francisco, with hubs across the United States, Australia, India, Ireland, Mexico and Türkiye. View source version on Contacts Investor ContactDennis WalshVice President, Investor Media ContactGlenn LehrmanVice President, Communicationspress@

Globalstar and CERES TAG Partnership Support Livestock Industry Amid New World Screwworm Threat
Globalstar and CERES TAG Partnership Support Livestock Industry Amid New World Screwworm Threat

Associated Press

time4 minutes ago

  • Associated Press

Globalstar and CERES TAG Partnership Support Livestock Industry Amid New World Screwworm Threat

COVINGTON, La.--(BUSINESS WIRE)--Jun 24, 2025-- Globalstar (NASDAQ: GSAT), a next-generation telecommunications infrastructure and technology provider, announces its continued partnership of delivering critical global connectivity for the agricultural technology solutions developed by CERES TAG, the world's leading animal health intelligence platform, as it prepares its readiness in the event of an outbreak of the New World Screwworm. As the livestock industry in Mexico grapples with the recent outbreak of this vector-borne disease, the powerful partnership between Globalstar and CERES TAG is critical in helping producers and authorities to act quickly and contain the spread of the disease. The outbreak, which has led to the recent border closure to live animal imports, has placed cattle producers on high alert. The New World Screwworm seriously threatens animal welfare and herd productivity, with potential economic fallout measured in hundreds of millions of dollars if not swiftly contained. Over the last decade, the economic impact of zoonotic diseases has been estimated to be $20 billion, directly, and $200 billion indirectly. CERES TAG's smart ear tags enable livestock monitoring through real-time behavioral data, GPS location, and biosecurity triggers, all transmitted without reliance on cellular infrastructure. Globalstar's satellite network ensures uninterrupted connectivity across even the most remote ranches. 'These are extremely devastating events,' CERES TAG Founder and CEO David Smith said. 'But you can limit damage by supporting real-time traceability and detection with technology like what CERES TAG offers. We have advanced algorithms developed by researchers worldwide, but it's hopeless if we can't communicate that information when there's a trigger. Globalstar is an integral partner in all of this.' 'Satellite technology is no longer just a backup; it's a core infrastructure of agricultural intelligence,' Globalstar Vice President of Global Sales Jake Rembert said. 'We're proud to support CERES TAG in delivering real-world solutions that help protect food security and animal health globally.' As more frequent and widespread zoonotic diseases emerge, ranchers and governments are investing in next-generation solutions that combine intelligent sensing with resilient connectivity. CERES TAG has recently expanded into the United States and committed to Globalstar a minimum of 30,000 units for the remainder of the year. CERES TAG just signed agreements with the two largest animal health organizations in the United States – MWI Health and Animal Health International. About Globalstar, Inc. Globalstar empowers its customers to connect, transmit, and communicate smarter – easily, quickly, securely, and affordably – offering reliable satellite and terrestrial connectivity services as an international telecom infrastructure provider. The Company's low Earth orbit ('LEO') satellite constellation ensures secure data transmission for connecting and protecting assets, transmitting critical operational data, and saving lives for consumers, businesses, and government agencies across the globe. Globalstar's terrestrial spectrum, Band 53, and its 5G variant, n53, offer carriers, cable companies, and system integrators a versatile, fully licensed channel for private networks with a growing ecosystem to improve customer wireless connectivity, while Globalstar's XCOM RAN product offers significant capacity gains in dense wireless deployments. In addition to SPOT GPS messengers, Globalstar offers next-generation Internet of Things ('IoT') hardware and software products for efficiently tracking and monitoring assets, processing smart data at the edge, and managing analytics with cloud-based telematics solutions to drive safety, productivity, and profitability. For more information, visit About CERES TAG CERES TAG is a pioneering Australian company specializing in direct-to-satellite animal health intelligence technology. The company's innovative solutions provide real-time tracking and data analytics for livestock and wildlife, enhancing productivity, profitability and sustainability in the agriculture and conservation sectors. CERES TAG has recently expanded with a new Americas Head Office located in Kansas City | View source version on CONTACT: Media Contact: Alisa Moloney [email protected] KEYWORD: UNITED STATES NORTH AMERICA LOUISIANA INDUSTRY KEYWORD: MOBILE/WIRELESS TECHNOLOGY ANIMAL WELFARE AGRITECH SATELLITE TELECOMMUNICATIONS PUBLIC POLICY/GOVERNMENT NETWORKS AGRICULTURE NATURAL RESOURCES SOURCE: Globalstar, Inc. Copyright Business Wire 2025. PUB: 06/24/2025 09:17 AM/DISC: 06/24/2025 09:16 AM

GeoVax Comments on FDA Approval of Keytruda(R) in Head and Neck Cancer, Underscoring Potential for Gedeptin(R) Combination Therapy
GeoVax Comments on FDA Approval of Keytruda(R) in Head and Neck Cancer, Underscoring Potential for Gedeptin(R) Combination Therapy

Associated Press

time4 minutes ago

  • Associated Press

GeoVax Comments on FDA Approval of Keytruda(R) in Head and Neck Cancer, Underscoring Potential for Gedeptin(R) Combination Therapy

Supports Advancement of GeoVax's Phase 2 Gedeptin(R) Trial in Recurrent Head and Neck Cancer ATLANTA, GA - June 24, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today commented on the U.S. Food and Drug Administration's recent approval of Keytruda(R) (pembrolizumab) for use in resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) tumors expressing PD-L1 as determined by an FDA approved test. This regulatory milestone marks a significant advancement in the curative-intent treatment landscape for head and neck cancer and affirms the therapeutic strategy underlying GeoVax's Gedeptin(R) development program. An editorial by Rosenberg and Vokes in New England Journal of Medicine (NEJM) noted that the study forming the basis of FDA's approval represents the first demonstration of benefit for PD-1 inhibition in the curative setting for HNSCC, with implications for evolving neoadjuvant immunotherapy paradigms. GeoVax is planning to initiate a Phase 2 clinical trial of Gedeptin(R) in combination with a checkpoint inhibitor, such as pembrolizumab, in patients with locally advanced HNSCC scheduled for curative-intent surgery. The trial aims to improve tumor clearance and reduce relapse by combining the immune-priming effect of Gedeptin's targeted cytotoxicity with the systemic immune activation of checkpoint inhibition. The Phase 2 study, expected to launch in 2026, will evaluate pathologic response, recurrence rates, and biomarker-defined immunologic changes when Gedeptin is used as neoadjuvant therapy with checkpoint inhibitors. Importantly, the NEJM editorial emphasized the need to optimize patient selection and treatment duration in the immunotherapy era, aligning with GeoVax's biomarker-driven approach. 'The NEJM publication and FDA approval of Keytruda in resectable HNSCC signals a new era in curative-intent cancer therapy,' said David Dodd, Chairman and CEO of GeoVax. 'By combining Gedeptin therapy with pembrolizumab, we aim to enhance local tumor eradication while unlocking systemic anti-tumor immunity, potentially reducing both local and distant recurrence.' 'We believe Gedeptin's tumor-targeted cytotoxicity can enhance immunotherapy efficacy, particularly in the perioperative window where anti-tumor immunity can be primed,' added Dr. Kelly McKee, GeoVax's Chief Medical Officer. 'We are excited to embark on the next phase of Gedeptin development as we attempt to build on the important advances being made in this disease.' For more information about the KEYNOTE-689 study, see the June 18, 2025 publication in the New England Journal of Medicine. About Gedeptin Gedeptin(R) is a gene-directed enzyme prodrug therapy (GDEPT) delivered intratumorally via an adenoviral vector encoding purine nucleoside phosphorylase (PNP). Upon systemic administration of fludarabine, the enzyme catalyzes the generation of a cytotoxic agent selectively within the tumor microenvironment. This mechanism provides dual cytotoxicity and immune modulation with minimal systemic exposure. Gedeptin has been granted Orphan Drug Designation by the FDA for the treatment of oral and pharyngeal cancers and is protected by a growing intellectual property portfolio. GeoVax's ongoing innovation in immune-sensitizing therapies supports a broader strategy to complement checkpoint inhibitors and overcome tumor immune resistance across solid tumor types. About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: Forward-Looking Statements This release contains forward-looking statements regarding GeoVax's business plans. The words 'believe,' 'look forward to,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'could,' 'target,' 'potential,' 'is likely,' 'will,' 'expect' and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax's immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax's viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax's immuno-oncology products and preventative vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Company Contact: [email protected] 678-384-7220 Investor Relations Contact: [email protected] 212-698-8696 Media Contact: Jessica Starman [email protected]

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store